Vascular Biogenics (VBLT) Posts Earnings Results, Misses Estimates By $0.03 EPS

Vascular Biogenics (NASDAQ:VBLT) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03), Fidelity Earnings reports. The company had revenue of $0.16 million during the quarter.

Shares of NASDAQ:VBLT traded down $0.05 during trading on Friday, hitting $2.15. 15,184 shares of the stock were exchanged, compared to its average volume of 310,601. Vascular Biogenics has a 1-year low of $2.22 and a 1-year high of $2.22. The firm has a market capitalization of $66.52 million, a PE ratio of -5.81 and a beta of -1.69.

A number of analysts have issued reports on VBLT shares. Zacks Investment Research lowered Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Thursday, January 25th. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. HC Wainwright lowered Vascular Biogenics from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a report on Thursday, March 8th. Piper Jaffray lowered Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Thursday, March 8th. Finally, JMP Securities lowered Vascular Biogenics from an “outperform” rating to a “market perform” rating in a report on Thursday, March 8th. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. Vascular Biogenics currently has an average rating of “Hold” and an average target price of $3.19.

Large investors have recently made changes to their positions in the company. IFP Advisors Inc grew its holdings in shares of Vascular Biogenics by 339.7% during the 4th quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 15,117 shares in the last quarter. Alps Advisors Inc. acquired a new stake in shares of Vascular Biogenics during the 4th quarter worth approximately $234,000. ARK Investment Management LLC acquired a new stake in shares of Vascular Biogenics during the 4th quarter worth approximately $302,000. Finally, Raymond James & Associates grew its holdings in shares of Vascular Biogenics by 71.5% during the 4th quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 23,124 shares in the last quarter. 5.49% of the stock is currently owned by institutional investors.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit